… We adopted an industry-independent noninterventional retrospective evaluation on the
basis of the paper and electronic records complemented by personal information on the part of …

… We conducted a single-center retrospective observational study of patients with DRE who
received PER as add-on therapy at the Epilepsy Center of the People's Hospital of Henan …

… Force in 2009, drug-resistant epilepsy is defined … patients with epilepsy eventually fall
into drug-resistant epilepsy (DRE) [2], [3]. Among these patients, some have highly drug-resistant …

… of perampanel (PER) in association with 1 or 2 concomitant antiseizure medications (ASMs)
in patients … The majority of these studies evaluated the use of PER in drug-resistant epilepsy …

… This study investigated the efficacy and safety of perampanel (PER) adjunctive therapy in
pediatric patients with epilepsy whose seizures are pharmacoresistant to existing antiepileptic …

… Perampanel (PER) is a novel antiepileptic drug approved as an add-on therapy for focal
onset … to evaluate PER efficacy and tolerability as add-on therapy in patients with drug-resistant …

… to evaluate the efficacy and safety of perampanel (PER) in adult patients with drug-resistant …
adverse effects of PER in thirty-three adult patients (mean age 31.6 years, range 19-55) with …

… Flow chart showing the patient inclusion process for … patients who started receiving
perampanel (PER) as an add-on therapy were initially enrolled in this study. At 6 months: 24 patients …

… this highly drug-resistant population. However, retention rates were similar among the studies
suggesting that the tolerability was similar. Another explanation may be differences in how …

… However, few studies have investigated PER in pediatric patients with DRE … , perampanel
is often the drug of choice in patients with DRE; we have observed that many of our patients …